These mechanisms (i.e., BCL2 gains, TP53 aberrations, and 13q14.2 deletions) contribute to BCL2 protein overexpression in virtually all MCL and lymphoplasmacytic lymphomas. This evidence concerns the gene TP53 and mantle cell lymphoma.